Brief: Shanghai Junshi Biosciences Says Indications Of Tuoyi & Mindewei Included In National Reimbursement Drug List
13/12/2023 15:57
Dec 13 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* NEW INDICATIONS OF TUOYI AND MINDEWEI INCLUDED IN NEW
EDITION OF
NATIONAL REIMBURSEMENT DRUG LIST
Source text for Eikon: ID:nHKS1RT8YQ
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences Co
See all newsBrief: Shanghai Junshi Biosciences Approved Proposal On Change In Shareholding Structure Of Implementing Entity Of Some Sub-Projects
Brief: Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint
Brief: Shanghai Junshi Biosciences Posts Quarterly Net Loss Attributable RMB20.6 Million
Brief: Shanghai Junshi Biosciences Says Shanghai Tanying Plans To Reduce Its Holdings Of Co's Shares
Brief: Shanghai Junshi Biosciences Says From 12 April 2025 To 31 March 2026, Chair Increased Stake